18^th European Biosimilars Congress

Biosimilars and Cancer

Biosimilars have emerged as a promising development in the field of oncology, offering new avenues for the treatment of cancer. These specialized biologic drugs are designed to be highly similar to existing, FDA-approved reference biologics, and they have the potential to provide cost-effective alternatives for cancer patients. Biosimilars can target various aspects of cancer management, including tumor cell growth inhibition, immune system modulation, and supportive care. By providing more affordable options for cancer therapies, biosimilars can help reduce the financial burden on patients and healthcare systems while expanding access to high-quality cancer treatments.